Canaccord’s Kyle Rose is impressed that not only did HSGX achieve its goal to nab a partnership by the year’s end, but the partner in Japan is a stellar choice with experience in regenerative medicine.
MYOS RENS Tech Inc (NASDAQ:MYOS) shares are falling 23% in pre-market trading, after the biotherapeutics company published an action against RENS Technology in the Supreme …
Based in Waltham, MA, Histogenics (NASDAQ:HSGX) scheduled a $60 million IPO on Nasdaq with a market capitalization of $151 million at a price …
